Your session is about to expire
← Back to Search
Immunomodulator
Active EC-18 for Coronavirus Pneumonia
Phase 2
Waitlist Available
Research Sponsored by Enzychem Lifesciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7, 14, and 28 days
Awards & highlights
Study Summary
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
Eligible Conditions
- Coronavirus Pneumonia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7, 14, and 28 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7, 14, and 28 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of patients alive and free of respiratory failure through at Day 28
Secondary outcome measures
Assessment of all-cause mortality
Confirmation of changes in subject's subjective clinical symptoms (e.g., patient questionnaire)
Lengths of ICU stay
+6 moreTrial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active EC-18Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mosedipimod
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Enzychem Lifesciences CorporationLead Sponsor
6 Previous Clinical Trials
329 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger